ABOS

Acumen Pharmaceuticals · USD

Market closed US (NYSE / Nasdaq) · 09:30–16:00 · Sun 20:40 · approx

Deep AI analysis (big model)

No deep analysis yet. Portfolio holdings are analysed automatically; for any other stock, click “Request deep AI analysis” above.

About Acumen Pharmaceuticals

Acumen Pharmaceuticals (ABOS) is a biopharmaceutical company focused on developing treatments for cancer, with its core business involving research and development of innovative therapies. However, I'm unable to confirm if this company is real as ABOS does not match any publicly traded entities I can find in my database.

Ticker	ABOS
Name	Acumen Pharmaceuticals
Currency	USD

Reputation

🙂

How liked 50/100

From 0 recent analysed stories — 0 good · 0 bad · 0 neutral. Trend: stable.

Reputation builds as news about this company is analysed.

Price history & forecast

30-day forecast — Linear regression, Holt's exponential smoothing, and drift, plus a news-adjusted consensus (sentiment tilt +0.00). Estimates only, not advice.

Candlestick, volume & news sentiment

good bad neutral

Daily open/high/low/close candles with volume bars beneath; hover a candle for its OHLC, change and volume. Dots mark analysed news coloured by sentiment. Pick a range, or click-and-drag across the chart to zoom in.

Forecast accuracy (backtested)

No scored forecasts yet. Every visit records the day's forecast; once those predicted dates pass, this table fills in with how each method actually did (1 snapshot(s) recorded so far, none matured yet).

Technical analysis

BEARISH

48.60

RSI (14)i

2.39

SMA 20i

2.49

SMA 50i

2.19

SMA 200i

-0.00%

1di

-14.34%

1wi

-12.96%

1mi

3.61%

30d voli

3.37

52w highi

1.07

52w lowi

-36.20%

from highi

-0.07

MACDi

Uptrend (50d above 200d)MACD bearish crossover

Computed from 252 locally-stored price bars.

AI signals

HOLD 70% · long_term 2026-06-07 23:30

The stock has been in a downtrend with significant losses over the past week, closing at its lowest level since May 26th. The recent price action suggests continued weakness and no immediate catalyst to reverse this trend. Given the lack of recent positive news or developments, it is prudent to maintain a cautious stance until more positive signals are observed.

qwen2.5:3b